compani
rais est solid global volum
growth increas pt
focu
rais sales/ep vs street
trial show benefit best harm least data elanco ipo
add dri powder must-win oncolog armo/ aurka add
string pearl strategi new use add leg immunolog growth emerg
pain franchis support emgality/lasmiditan migrain tanezumab oa
pain reiter buy/pt ep support
dcf
rais est top-end rang solid op execut
second time ytd click postview rais sales/
ep high-qual beat rais quarter click
initi thought rais sales/ep
vs street higher oncolog
diabet cardiovascular sale along higher gross
margin partial off-set higher opex sales/ep
top-end lli updat rang note biopharma
preview click note recommend investor accumul share
compani drive global sale growth volum gain new
product launch lli beat rais perform demonstr
solid execut paus us price increas pend transpar
polici implic administr blueprint view impact hh
new propos regul remov safe harbor protect rebat
increas transpar net price offic manag
budget omb complet review like ye nonetheless believ
growth compound-annual-growth-rate next five year expect drive earn growth
faster sale compound-annual-growth-rate uptick gross margin fix
cost leverag yield oper margin expans expect
transpar rise lli emerg pain segment fda action
emgal cgrp late migrain prophylaxi lasmiditan acut
migrain file tanezumab data set oa/low back pain
diabet assum trulic rewind cv outcom trial show
benefit best harm least data expect think lli
tr target
compani
could yield valu time ad balanc sheet
strength depend structur and/or share repurchas board author new
repo program host investor event dec highlight pipelin progress issu
financi rang reiter buy increas pt pt ep
risk includ price pressur commerci execut regulatori clinic trial risk note
major biopharma group outperform last month vs
 last month vs attract risk reward sinc trade
discount index remain one favorit large-cap growth name along
bristol-my buy larg cap valu like buy mid-cap growth like
trulic downsid limit long rewind show harm
offset declin short-act insulin humalog/humulin us market
trulic achiev leadership prescript overtak novo nordisk novo b-dk
rate victoza market grow yoy think nvo ozemp data
impart cv-benefit effect entir class assum trulic rewind data show
cv benefit best harm least limit downsid risk top-lin releas full data
assum ada trulic enjoy full access nvo ozemp limit payer
access blunt competit threat ytd inject becom standard care due
superior lower effect weight loss complianc once-weekli dose view
oral semaglutid welcom addit oral class drug click note repres
potenti disrupt competit asset model trulic sale vs street
jardianc cv ckd benefit util hf underappreci
 boehring ingelheim privat jardianc categori leader us trx/nbrx
market share expect jardianc heart failur hf pivot trial emperor-
reduc emperor-preserv show rapid signific benefit primari cv endpoint
potenti data compel enough result earli stop interim analys lly/bi also
plan initi jardianc chronic kidney diseas ckd trial posit data johnson
 johnson rate invokana renal outcom trial credenc click note
posit data renal data empa outcom click give us high confid posit
read-out jardianc trial ckd addit expect class volum trend bolster
astrazeneca azn-gb rate declar cv outcom data farxiga model
jardianc allianc revenu vs street
tradjenta show cv benefit basaglar share gain
lly/bi tradjenta achiev posit cardiovascular cv outcom carmelina studi underl
competit advantag drug class includ merck buy class-
lead januvia fail achiev similar result click note conting data
carolina studi would expect lly/bi file tradjenta cv outcom data review late
earli model tradjenta allianc revenu vs street lli biosimilar
insulin glargin basaglar gain us nbrx/trx share expens nvo sanofi san-
fr rate model basaglar sale vs street pipelin front
expect share result co-agonist annual confer
european associ studi diabet easd oct berlin germani
investor call present expect initi program late
earli note high bar efficaci move molecul phase given
competit intens categori phase result met high bar think lli diabet
growth asset counter on-going declin humalog/humulin posit doubl
diabet franchis base
oncolog growth driven verzenio/alimta still need
lli alimta expect secur label expans front-lin non-smal cell lung cancer nsclc
use combin keytruda chemo base robust progression-fre surviv overal
surviv os benefit seen mrk data click note on/befor sept
pdufa date ip front district court rule manufactur altern salt
form alimta pemetrex us lost patent rule germani plan appeal
german court decis delay gener alimta launch see downsid modest lose
page
compani
appeal sinc germani account alimta sale global revenu
model alimta sale vs street lli verzenio abemaciclib shown
earli success breast cancer market us nbrx share approach ahead
novarti nv rate kisqali note uptak encourag three breast cancer
set monotherapi fulvestrant-combo aromatas inhibitors-combo accord
market grow yoy current penetr suggest signific room
growth particularli prescrib appreci verzenio continu dose single-ag activ
differenti clinic characterist ex-u verzenio receiv posit chmp opinion
combin aromatas inhibitor fulvestr metastat breast cancer
juli expect approv late model global verzenio sale
significantli street along growth product like cyramza lartruvo etc
intrigu asset intern oncolog pipelin howev oncolog area
need continu sourc extern innov view consid oncolog must-win area
oncolog grow compound-annual-growth-rate per industri research
need better posit sustain long-term sale growth two oncolog acquisit
ytd aurka click note armo click suggest take string
pearl strategi oncolog
immunolog expect continu geograph label expans taltz olumi put upward
pressur street estim out-year model combin taltz/olumi sale
street addit outsid taltz olumi deep pipelin includ
mirikizumab inhibitor psoriasi ulcer coliti crohn diseas
btk inhibitor rheumatoid arthriti least seven asset
bsab mab mab bsab pegyl inhibitor
taltz growth benefit deep psoriasi market penetr
lli taltz show robust growth sale yoy/qoq
psoriasi pso despit competit novarti novn-ch rate cosentyx jnj
tremfya nv state call click note pso market begin
bifurc monoclon antibodi cosentyx retain lead share
howev challeng taltz saw nbrx share dermatolog derm climb
qoq addit plan initi head-to-head pso studi evalu taltz vs
tremfya think lli studi along jnj eclips trial tremfya vs cosentyx
pso read-out increas derm interest awar next-
gener asset also work diversifi taltz revenu psoriat arthriti launch
us/eu dec approv sbla file ankylos spondyl
expect click note model taltz sale vs street
olumi disadv dose half xeljanz xr price
think lli us price strategi olumi treatment rheumatoid arthriti ra
partial mitig disadvantag secur approv higher dose expect
physician titrat close pariti price wac basi hold
xeljanz/xr click note titl olumi us approv label exclus
ra-beacon outsid us olumi launch ra dose approv
proceed well sale yoy/qoq particularli europ led
germani olumi lead driver volum growth across portfolio lli olumi
label expans strategi includ on-going upcom pivot trial indic like atop dermat
ad five on-going psoriat arthriti initi system lupu erythematosu
sle roll-out data publish lancet alopecia adapt roll-out
model olumi sale vs street
emgal put pain franchis posit hit ground run
lli emerg pain franchis repres compani fourth leg growth diabet
immunolog oncolog lli pain franchis enter import commerci phase
launch emgal galcanezumab expect lasmiditan nda file final data
tanezumab expect fda action lli cgrp emgal prophylact treatment
chronic/episod migrain cm/em late fda accept bla dec view
page
compani
emgal import opportun lli new pain franchis assum teva teva-il
rate fremanezumab secur approv septemb pdufa date cgrp
approv long celltrion rate resolv manufactur issu
note teva manufactur partner celltrion like undergon fda review
manufactur facil south korea agenc recent issu two label updat base review
two south korean facil celltrion biosimilar inflectra samsung biolog facil
rate biosimilar renflexi manufactur although rate novarti
aimovig enter first- cgrp migrain space may think emgal earli onset
action prolong mainten efficaci clinic data reduct migrain case click
note differenti class addit emgal shown benefit episod
cluster headach view could halo effect cm/em indic sinc neurologist
like adopt use quickli difficult-to-treat popul click note entitl
cgrp show efficaci benefit debilit cluster headach note
howev commit file cluster headach say pleas
result saw phase studi well certainli discuss regul
commerci expect price emgal pariti aimovig wac
price competit access occur net price level assum meaning chang
legal framework around discounts/reb near-term lastli think aimovig unpreced
demand click bode well lli emgal launch model emgal sale
street
lasmiditan track file acut migrain
acut migrain expect receptor agonist lasmiditan la well-posit
take share approv click jan deep dive lasmiditan collect long-term
safeti data gladiat la conduct drug-drug interact drive studi ahead nda
file expect la us approv la sale street
also develop anti-nerv growth factor ngf monoclon antibodi tanezumab
collabor osteoarthr oa hip knee chronic low back pain clbp
pfe/lli tanezumab met three co-primari endpoint phase oa trial
rapidly-progress oa/osteonecrosi tanezumab patient allay
headlin safeti concern asset howev note call
oa trial wasnt design discharg safeti risk continu view tanezumab high-risk/
high-reward clinic asset see posit data long-term safeti studi expect
pfe/lli share full result efficaci studi upcom medic confer
like world congress pain wcp sept boston three remain trial
low back pain tango expect read earli assum oa data posit
 lt safeti show issu pfe/lli target file tanezumab posit
non-opioid altern oa us pt clbp tanezumab add high-margin allianc
revenu lli emerg pain franchis model vs street
neurosci earli pipelin display aaic confer
review alzheim diseas pipelin alzheim associ intern confer
aaic chicago il juli see exhibit summari key session find
import session publish juli version journal alzheim associ
despit multipl setback includ high-profil failur solanezumab click note titl
solanezumab miss statist signific lower pt alzheim diseas
ad novemb discontinu monotherapi bace inhibitor program ad june
click note titl lly/azn bace inhibitor discontinu read-across
class remain commit neurosci franchis pursu
monoclon antibodi target ad conclud studi
activ bind amyloid- dose regimen appear safe despit modest immunogen
initi earli symptomat ad patient trial aim recruit patient
primari complet date march addit collabor azn continu
pursu develop bace inhibitor combo base intrigu
anim model click also pursu oral compound act dopamin
receptor enhanc treatment parkinson diseas dementia current enrol
patient trial presenc primari complet juli also
collabor azn develop amyloid- inhibitor final still evalu
page
compani
solanezumab pre-symptomat ad patient amyloid plaqu show sign
dementia patient inherit mutat caus ad due overproduct
amyloid plaqu carri meaning revenu asset model
neurosci pipelin becom de-risk clinic could see materi upward pressur our/
street long-term sales/ep estim
state us major biopharma preview see note think polit pressur payer
consolid strong balanc sheet lower tax rate support thesi price pressur
trigger wave announc deal ytd involv ex-u buyer
earn call manag reiter appetit pursu ceo note
mostli interest clinical-stag asset build core five therapeut area
armo acquisit exampl kind thing interest end
cash equival net debt/ebitda ratio think could pursu
acquisit larg without requir signific sharehold dilut assum
focus primarili earlier-stag pipelin opportun rang depend
structur alloc proce plan divest ipo
later tax-advantag divestitur remain could potenti yield
total valu click initi thought elanco ipo could boost lli capac
must-win oncolog area state earlier click note titl ceo focus
sharehold valu rais pt announc elanco strateg review
octob think divest elanco made strateg sens sharehold financi
note think could fetch total impli enterpris valu
ipo busi depend alloc ipo proce whether retain
proce distribut exist sharehold could add signific amount dri
powder lli balanc sheet
elanco sales/earn remain model
model perspect retain elanco within model line plan
includ elanco full-year financi rang ipo complet ipo
complet full dispos elanco retain ownership includ
consolid elanco result financi rang minor interest distribut back ep
consist divestitur account rule final fulli dispos remain interest
elanco updat rang year base sole remain busi unit
contribut elanco year prior separ reflect discontinu oper
page
exhibit lli present alzheim associ intern confer aaic
trailblazer-alz phase disease-modif combin therapi trial target multipl mechan action along
amyloid pathway
safeti toler pharmacokinet pharmacodynam singl multipl intraven dose
amyloid plaque-specif antibodi patient mild cognit impair due alzheim diseas mild moder
lanabecestat screen perform amaranth studi
baselin characterist particip random phase amaranth studi
lanabecestat affect pharmacokinet bcrp substrat rosuvastatin
relationship tau pet ad biomark autosom domin alzheim diseas
relationship tau pet age across lifespan
role inhibit patholog age pdapp mice
compani
use digit clock draw test dctclock screen phase clinic trial alzheim diseas
impact disclos amyloid imag result cognit normal research experi
anti-amyloid treatment asymptomat ad study- report screen data result
dian-tu adapt prevent trial launch baselin data
predict amyloid burden screen preclin ad prevent trial
tau pet preliminari report
computer cognit composit perform differ a- normal older adult screen
anti-amyloid asymptomat ad studi
brain amyloid burden sleep circadian rest/act rhythm baselin find
lobar classif tau pet imag trial
alzheim diseas tau pet subtyp adni sampl
pattern chang depend level commun dwell alzheim patient result gera
minim clinic import differ estim clinic outcom assess alzheim diseas differ
model patient engag alzheim diseas mopead european multi-national project develop test
baselin find geras-u longitudin cohort studi resourc use cost mild cognit impair
mild dementia due alzheim diseas ad unit state
standard qualiti control regul issu fluid biomark topic workshop basic fluid
biomark alzheim diseas
biomark
biomark
alzheim diseas comparison three volumetr mri z-score norm method across alzheim diseas spectrum
biomark
biomark
alzheim diseas simpl method defin atrophi subtyp individu subject across alzheim diseas spectrum
biomark
biomark
biomark
alzheim diseas map genom consequ alzheim diseas patholog amyloid tau mous
strh research aaic note import present highlight blue color import present highlight grey
subtyp neurodegener alzheim diseas head-to-head comparison four brain atrophi subtyp
algorithm adni
measur endogen mous tau cerebrospin fluid age pdapp mice follow treatment lower
age-norm diffus basi spectrum imag dbsi cell ratio assess neuroinflamm alzheim diseas
page
compani
one-off guidanc updat sigilon deal
page
compani
sale
sale
page
compani
exhibit estim strh vs consensu
page
compani
page
compani
page
compani
exhibit incom statement
sale
page
compani
exhibit consolid balanc sheet
total liabil sharehold equiti
equival
st borrow current portion lt debt
accumul comprehens loss
common stock treasuri
page
compani
exhibit statement
chang defer tax
net oper
restrict cash releas acquisit
dispos prop equip
addit asset
reduct invest
addit invest
net invest
purchas common stock
chang st borrow cpltd
addit long-term debt
reduct long-term debt
net financ
effect exchang rate
cash/equival begin period
cash/equival end period
page
compani
lilli lead research-bas biopharmaceut compani focus drug discoveri
clinic develop manufactur commerci pharmaceut product human
anim diseas gener sale yoy gener
us ex-u market human medicin busi includ core franchis
neurosci diabet women oncolog cardiovascular contribut
 total sale global leader diabet arena new product
trulic basaglar collabor asset jardianc tradjenta lli oncolog franchis
compris inhibitor verzenio abemaciclib alimta cyramza portrazza lartruvo
also place stake ground establish immunolog franchis
launch taltz olumi lli fourth leg emerg growth target pain market
three late-stag asset galcanezumab lasmiditan tanezumab enter one
best new product cycl year histori new product launch trulic jardianc
rate buy base attract low-teen earn growth mid-singl
digit volum driven sale growth commit expand oper margin tight
cost manag new product cycl unfold
model assum doubl diabet franchis level
jardianc basaglar trulic offset declin establish product
humalog humulin expect jardianc take materi share market older
gener therapi owe cardiovascular-benefit estim share shift
older gener therapi jardianc equat sale conting discount rebat
put upward pressur out-year estim also expect doubl
oncolog franchis base support verzenio alimta cyramza
portrazza lartruvo verzenio third-to-market inhibitor segment multipl use
breast cancer market alimta expect benefit combo use keytruda first-lin non-
small cell lung cancer nsclc alimta alreadi substanti presenc non-squam
nsclc market model assum maintain us exclus alimta
immunolog taltz olumi baricitinib expect contribut sale
think olumi long-term growth benefit expand asset commerci reach much
possibl geograph eu/japan label expans atop dermat system lupu
erythematosu psoriat arthriti taltz posit captur mid-teen percentag psoriasi
treat patient popul next five year lastli lli emerg pain franchis repres
fourth leg growth differenti late-stag asset significantli derisk galcanezumab
lasmiditan tanezumab galcanezumab robust efficaci placebo-lik safeti posit take
materi share cgrp market lasmiditan first-in-class molecul offer
cardiovascular safeti advantag acut migrain standard-of-car triptan
oper leverag margin expans central thesi compani contain fix
cost grow revenu base next five year lli streamlin oper
improv cost structur posit achiev opex goal sale
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
page
compani
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
amgen inc rate
astrazeneca plc azn-gb rate
celltrion inc rate
johnson johnson rate
novarti ag novn-ch rate
novo nordisk a/ novo b-dk rate
samsung biolog co ltd rate
sanofi san-fr rate
teva pharmaceut industri limit teva-il rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
